

---

**CORRIGENDUM**

## Metabolic targets for cancer therapy

Lorenzo Galluzzi, Oliver Kepp, Matthew G. Vander Heiden and Guido Kroemer

*Nature Reviews Drug Discovery* 12, 829–846 (2013)

There were some inaccuracies in the following sentence on p839 of the article: "Along similar lines, the pharmacological or genetic inhibition of phosphoglycerate mutase 1 (PGAM1) reduces tumour growth *in vitro* and *in vivo*, perhaps owing (at least in part) to the G6PD-inhibitory effects of 3-phosphoglycerate<sup>222</sup>. That said, genetic defects that have an impact on the enzymatic activity of G6PD are common among individuals living in geographical areas with a history of endemic malaria<sup>223</sup>."

The correct sentence is as follows: "Along similar lines, the pharmacological or genetic inhibition of phosphoglycerate mutase 1 (PGAM1) reduces tumour growth *in vitro* and *in vivo*, perhaps owing (at least in part) to the PPP-inhibitory effects of 3-phosphoglycerate<sup>222</sup>. That said, genetic defects that have an impact on the enzymatic activity of G6PD (and hence inhibit the PPP) are common among individuals living in geographical areas with a history of endemic malaria<sup>223</sup>."

This has now been corrected in the online version of the article.